PapersFlow Research Brief
Cutaneous lymphoproliferative disorders research
Research Guide
What is Cutaneous lymphoproliferative disorders research?
Cutaneous lymphoproliferative disorders research is the study of classification, staging, treatment, and prognosis of cutaneous lymphomas, with emphasis on mycosis fungoides and Sézary syndrome, including WHO-EORTC classification, survival outcomes, prognostic factors, and therapies such as bexarotene and denileukin diftitox.
This field encompasses 41,487 works on incidence patterns, genomic landscape, and molecular profiling of cutaneous T-cell lymphomas. Willemze (2005) introduced the WHO-EORTC classification for cutaneous lymphomas to address shortcomings in prior EORTC and WHO systems, particularly for cutaneous T-cell lymphomas. Swerdlow et al. (2016) revised the World Health Organization classification of lymphoid neoplasms, updating entities relevant to cutaneous lymphoproliferative disorders.
Topic Hierarchy
Research Sub-Topics
Mycosis Fungoides Classification and Staging
Researchers study histopathological, immunophenotypic, and molecular criteria for classifying and staging mycosis fungoides under WHO-EORTC frameworks. They develop refined staging systems and prognostic indices based on clinical cohorts.
Sézary Syndrome Genomic Profiling
This sub-topic covers next-generation sequencing, somatic mutations, and epigenetic alterations in Sézary syndrome. Studies identify driver mutations and therapeutic targets through large-scale genomic datasets.
Primary Cutaneous CD30+ Lymphoproliferative Disorders
Research focuses on clinicopathologic features, differential diagnosis, and outcomes of lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma. Investigators analyze expression profiles and long-term follow-up data.
Prognostic Factors in Cutaneous T-Cell Lymphomas
Studies identify clinical, histologic, and molecular predictors of survival in cutaneous lymphomas using multivariate analyses and validation cohorts. Researchers explore biomarkers like T-cell receptor clonality and blood involvement.
Targeted Therapies for Cutaneous Lymphomas
This area evaluates bexarotene, denileukin diftitox, mogamulizumab, and novel agents in refractory cutaneous lymphomas through phase II/III trials. Researchers assess response rates, toxicities, and resistance mechanisms.
Why It Matters
Research on cutaneous lymphoproliferative disorders informs clinical management of cutaneous lymphomas through standardized classifications and prognostic tools. The WHO-EORTC classification by Willemze (2005) resolves discrepancies in categorizing cutaneous T-cell lymphomas between prior systems, aiding accurate diagnosis and treatment selection. Swerdlow et al. (2016) updated the World Health Organization classification, incorporating hematopathology, genetics, and clinical consensus to refine entity definitions for improved staging and prognosis in conditions like mycosis fungoides. Poiesz et al. (1980) detected type C retrovirus particles in lymphocytes from a mycosis fungoides patient, establishing a viral association that advanced understanding of disease etiology. These contributions support therapies targeting prognostic factors and molecular profiles in dermatology and oncology practices.
Reading Guide
Where to Start
"WHO-EORTC classification for cutaneous lymphomas" by Willemze (2005) provides the foundational classification system integrating WHO and EORTC approaches, making it the ideal starting point for understanding cutaneous lymphoma categorization.
Key Papers Explained
Willemze (2005) "WHO-EORTC classification for cutaneous lymphomas" establishes a unified system resolving prior discrepancies, which Swerdlow et al. (2016) "The 2016 revision of the World Health Organization classification of lymphoid neoplasms" builds upon with broader lymphoid updates. Poiesz et al. (1980) "Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma" offers etiological insights into mycosis fungoides that complement classification efforts. Stein et al. (1985) "The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue" connects antigen expression to lymphoid activation, relevant to CD30+ cutaneous disorders.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Current frontiers emphasize incidence patterns, genomic landscapes, and molecular profiling of cutaneous T-cell lymphomas, as noted in the field description, with no recent preprints or news available to indicate shifts.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | The 2016 revision of the World Health Organization classificat... | 2016 | Blood | 7.6K | ✓ |
| 2 | Detection and isolation of type C retrovirus particles from fr... | 1980 | Proceedings of the Nat... | 5.0K | ✓ |
| 3 | WHO-EORTC classification for cutaneous lymphomas | 2005 | Blood | 3.8K | ✓ |
| 4 | Final Version of the American Joint Committee on Cancer Stagin... | 2001 | Journal of Clinical On... | 2.6K | ✕ |
| 5 | HISTOPATHOLOGY OF THE SKIN | 1950 | Plastic & Reconstructi... | 2.6K | ✓ |
| 6 | Adult T-cell leukemia: clinical and hematologic features of 16... | 1977 | Blood | 2.1K | ✕ |
| 7 | A systematic review of worldwide incidence of nonmelanoma skin... | 2012 | British Journal of Der... | 1.9K | ✕ |
| 8 | The expression of the Hodgkin's disease associated antigen Ki-... | 1985 | Blood | 1.8K | ✓ |
| 9 | High burden and pervasive positive selection of somatic mutati... | 2015 | Science | 1.8K | ✓ |
| 10 | KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Ce... | 2020 | New England Journal of... | 1.7K | ✓ |
Frequently Asked Questions
What is the WHO-EORTC classification for cutaneous lymphomas?
The WHO-EORTC classification, proposed by Willemze (2005), integrates World Health Organization and European Organization for Research and Treatment of Cancer systems to classify primary cutaneous lymphomas. It addresses differences in cutaneous T-cell lymphoma categorization found in prior EORTC and WHO classifications. This system improves diagnostic consistency for entities like mycosis fungoides and Sézary syndrome.
How was a retrovirus linked to cutaneous T-cell lymphoma?
Poiesz et al. (1980) detected type C retrovirus particles in T-cell lymphoblastoid cell lines HUT 102 and CTCL-3, and fresh peripheral blood lymphocytes from a mycosis fungoides patient. These cell lines continuously produce the viruses, which co-localize with T-cell markers. This finding connected retroviral infection to cutaneous T-cell lymphoma pathogenesis.
What updates occurred in the 2016 WHO classification of lymphoid neoplasms?
Swerdlow et al. (2016) revised the World Health Organization classification of lymphoid neoplasms after nearly eight years, reflecting consensus among hematopathologists, geneticists, and clinicians. The revision updates current entities and introduces new ones relevant to cutaneous lymphomas. It serves as the basis for the accompanying monograph on lymphoid neoplasms.
What are key treatments discussed in cutaneous lymphoma research?
Studies highlight treatments like bexarotene and denileukin diftitox for cutaneous T-cell lymphomas such as mycosis fungoides and Sézary syndrome. Research examines their efficacy alongside prognostic factors and survival outcomes. These therapies target clinical endpoints in primary cutaneous lymphomas.
What is the focus of research on CD30+ lymphoproliferative disorders?
Research addresses CD30+ lymphoproliferative disorders within primary cutaneous lymphomas, including classification and prognostic factors. Stein et al. (1985) showed Ki-1 antigen expression in Reed-Sternberg cells and histiocytic malignancies, linking them to activated lymphoid cells. This informs differentiation of reactive and neoplastic lymphoid tissue in cutaneous contexts.
Open Research Questions
- ? How do genomic landscapes and molecular profiles influence prognosis in mycosis fungoides and Sézary syndrome?
- ? What prognostic factors best predict survival outcomes in primary cutaneous T-cell lymphomas?
- ? How can classifications like WHO-EORTC be refined for emerging cutaneous lymphoproliferative entities?
- ? What role do retroviral particles play in the pathogenesis of cutaneous T-cell lymphomas beyond initial detections?
Recent Trends
The field includes 41,487 works with growth data unavailable over the past five years; foundational papers like Swerdlow et al. with 7618 citations and Willemze (2005) with 3766 citations remain highly influential, underscoring sustained focus on classification and lymphoid neoplasm revisions without new preprints or news in the last 12 months.
2016Research Cutaneous lymphoproliferative disorders research with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cutaneous lymphoproliferative disorders research with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers